Trial · NCT04808037
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT04808037, Phase 1, Phase 2, Active not recruiting, Hellenic Society of Hematology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma. Trials, record NCT04808037. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04808037
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- NCT number
- NCT04808037
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 66 participants, actual
- Lead sponsor
- Hellenic Society of Hematology
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- First posted
- 2021-03-19
- Last updated
- 2023-10-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with dose-limiting toxicities (DLTs) in each of the cohorts 1-3 | Five (5) years after last participant randomization | Determination of the safety and tolerability of belantamab mafodotin in combination with lenalidomide and dexamethasone to establish a recommended Phase 2 dose for participants with newly diagnosed Multiple Myeloma, transplant-ineligible |
| Primary | Overall Response rate as per IMWG by Investigator Assessment, defined as the percentage of participants with a confirmed PR, VGPR, CR or sCR | Five (5) years after last participant randomization | Evaluation of the preliminary clinical activity of the Recommended Phase 2 Dose of belantamab mafodotin in combination with lenalidomide and dexamethasone for participants with newly diagnosed Multiple Myeloma, transplant-ineligible |
| Primary | Number of participants with adverse events (AEs) and serious adverse events (SAEs) in each of the cohorts 1-3 | Five (5) years after last participant randomization | Determine the safety and tolerability of blmf in combination with lenalidomide and dexamethasone to establish a recommended Phase 2 dose for participants with newly diagnosed Multiple Myeloma, transplant-ineligible |
| Primary | Number of participants with adverse events (AEs) and serious adverse events (SAEs) in patients receiving the Recommended Phase 2 Dose | Five (5) years after last participant randomization | Further evaluation of the safety of Belantamab Mafodotin in combination with Lenalidomide and Dexamethasone |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04808037
GET https://conductscience.org/api/trials/v1/NCT04808037/registered